← Therapy pipeline
Investigational · Obesity development

Retatrutide

LY3437943 · Eli Lilly

A once-weekly triple agonist targeting GLP-1, GIP and glucagon.

GLP-1GIPglucagon
Other study areas
Type 2 diabetesLiver disease (MASLD / MASH)Sleep apneaKnee osteoarthritisCardiovascular outcomesKidney outcomesWeight maintenance / switchingChronic low-back pain
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 9, 2026
SponsorEli Lilly
TargetsGLP-1 + GIP + glucagon
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

TRIUMPH-1Mean body-weight reductionBody weight decreased 25% · 80 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Mean body-weight reduction · 80 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
25%
Placebo / comparator
3.9%

Adults with obesity or overweight and a complication, without diabetes · Retatrutide 12 mg weekly vs placebo · Trial N=2339 · Treatment-regimen estimand; intention-to-treat analysis in the published randomized Phase 3 trial. Results & methods ↗ · Publication ↗

Same trial · week-80 treatment-regimen estimand
Weekly doseWeight change
4 mg−17.6%
9 mg−23.7%
12 mg−25.0%
Placebo−3.9%
Additional results or analyses from this same study
  • Same trial · sponsor efficacy estimandThe sponsor reported 28.3% weight reduction with 12 mg versus 2.2% with placebo at 80 weeks under the efficacy estimand. Follow-up source ↗

Primary weight results use the treatment-regimen estimand. The sponsor efficacy-estimand values are a separate analysis of this same protocol; OSA-substudy outcomes are reported separately.

TRIUMPH-1 OA cohort · knee painWOMAC knee-pain score change (0–10 scale)WOMAC knee-pain score decreased 4.3 points · 80 weeks · Phase 3
Phase 3 · Injection · Primary conference abstract; related journal publication linked

WOMAC knee-pain score change (0–10 scale) · 80 weeks

Study focus: Knee osteoarthritis outcomes

Retatrutide 12 mg weekly
4.3 points decrease
Placebo
2.24 points decrease

Adults with BMI ≥27 and painful knee osteoarthritis, without diabetes · Weekly retatrutide versus placebo · Trial N=574 · Efficacy estimand, as reported in the ACR primary abstract. Results & methods ↗ · Publication ↗

Same-study WOMAC pain change · efficacy estimand · points
ArmChange from baseline
Retatrutide 4 mg−3.66
Retatrutide 9 mg−4.19
Retatrutide 12 mg−4.30
Placebo−2.24

Pain and weight outcomes do not establish prevention of structural joint damage or avoidance of joint replacement. Conference efficacy-estimand estimates differ from the journal’s other estimands. TRIUMPH-1 OA is a prespecified cohort of the existing master protocol, not an additional trial; its ACR presentation is scheduled for November 10, 2026.

TRIUMPH-4 · knee painWOMAC knee-pain score change (0–10 scale)WOMAC knee-pain score decreased 4.41 points · 68 weeks · Phase 3
Phase 3 · Injection · Primary conference abstract; related journal publication linked

WOMAC knee-pain score change (0–10 scale) · 68 weeks

Study focus: Knee osteoarthritis outcomes

Retatrutide 12 mg weekly
4.41 points decrease
Placebo
2.43 points decrease

Adults with BMI ≥27 and painful knee osteoarthritis, without diabetes · Weekly retatrutide versus placebo · Trial N=445 · Efficacy estimand, as reported in the ACR primary abstract. Results & methods ↗ · Publication ↗

Same-study WOMAC pain change · efficacy estimand · points
ArmChange from baseline
Retatrutide 9 mg−4.48
Retatrutide 12 mg−4.41
Placebo−2.43

Pain and weight outcomes do not establish prevention of structural joint damage or avoidance of joint replacement. Conference efficacy-estimand estimates differ from the journal’s other estimands. The ACR abstract was presented November 8, 2026.

Diabetes-focused studies

These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.

TRANSCEND-T2D-2Mean body-weight changeBody weight decreased 20.9% · 80 weeks · Phase 3
Phase 3 · Injection · Sponsor-reported topline; full peer-reviewed data pending

Mean body-weight change · 80 weeks

Study focus: Weight change in type 2 diabetes

Retatrutide 12 mg
20.9%
Semaglutide 2 mg
9.4%

Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor · Retatrutide 12 mg weekly vs semaglutide 2 mg weekly · Trial N=1298 · Efficacy estimand; Lilly sponsor-reported topline. Results & methods ↗

Additional results or analyses from this same study
  • Retatrutide 9 mgMean weight change was −19.5% (44.3 lb lost), compared with −9.4% (20.9 lb lost) with semaglutide 2 mg. Retatrutide 12 mg: −20.9% (47.4 lb lost). Efficacy estimand.
  • HbA1c at week 80Mean HbA1c decreased by 2.2 percentage points with both retatrutide doses versus 1.8 percentage points with semaglutide 2 mg; efficacy estimand.
  • Safety and risk factorsLilly reported greater improvements in triglycerides, non-HDL cholesterol and systolic blood pressure with retatrutide. Gastrointestinal adverse events were common. Dysesthesia occurred in 4.8%, 6.5%, and 2.7% and adverse-event discontinuation in 4.8%, 7.9%, and 2.7% with retatrutide 9 mg, 12 mg, and semaglutide, respectively.

Investigational retatrutide. These are sponsor-reported topline results; complete peer-reviewed data are pending. The efficacy estimand assumes treatment adherence.

TRIUMPH-2Mean body-weight changeBody weight decreased 18.8% · 80 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Mean body-weight change · 80 weeks

Study focus: Weight management with type 2 diabetes

80-week Phase 3 weight-management trial in adults with type 2 diabetes.

Investigational regimen
18.8%
Placebo / comparator
5.1%

Adults with obesity or overweight and type 2 diabetes · 12 mg weekly vs placebo · Trial N=1152 · Treatment-regimen estimand; randomized participants included regardless of treatment discontinuation. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Other doses · treatment-regimen estimandMean weight changes at week 80: 4 mg −11.9%; 9 mg −16.8%; placebo −5.1%.
  • Same trial · efficacy estimandAt 12 mg, weight change was −20.8% versus −4.0% with placebo under the efficacy estimand, which estimates continued treatment. This is a different analysis of the same trial. Follow-up source ↗

Gastrointestinal adverse events were common. Permanent discontinuation due to adverse events or death occurred in approximately 8% at 12 mg versus 5% with placebo.

TRIUMPH-3Mean body-weight changeBody weight decreased 22.6% · 80 weeks · Phase 3
Phase 3 · Injection · Sponsor-reported numerical results

Mean body-weight change · 80 weeks

Study focus: Weight management with cardiovascular disease

Weight and risk factors improved; cardiovascular-event reduction was not established.

Investigational regimen
22.6%
Placebo / comparator
3.2%

Adults with BMI ≥35 and established cardiovascular disease, with or without diabetes · 12 mg weekly vs placebo · Trial N=1949 · Efficacy estimand; sponsor topline. Results & methods ↗

MACE-3 HR 1.12 (95% CI 0.64–1.96), pooled retatrutide versus placebo; few events limit inference.

TRIUMPH-4Mean body-weight changeBody weight decreased 28.7% · 68 weeks · Phase 3
Phase 3 · Injection · Primary conference abstract

Mean body-weight change · 68 weeks

Study focus: Weight management with knee osteoarthritis

WOMAC pain improved 4.4 vs 2.4 points at 12 mg.

Investigational regimen
28.7%
Placebo / comparator
2.1%

Adults with obesity/overweight and knee osteoarthritis, without diabetes · 12 mg weekly vs placebo · Trial N=445 · Efficacy estimand; primary ACR abstract (previously sponsor topline). Results & methods ↗ · Publication ↗

These efficacy-estimand weight results are retained separately from the journal’s treatment-regimen analysis and from the WOMAC pain endpoint.

Diabetes-focused studies

These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.

TRANSCEND-T2D-1Mean body-weight changeBody weight decreased 15.3% · 40 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Mean body-weight change · 40 weeks

Study focus: Glycemic control in type 2 diabetes

HbA1c decreased 1.94 vs 0.81 percentage points.

Investigational regimen
15.3%
Placebo / comparator
2.6%

Type 2 diabetes inadequately controlled by diet and exercise; BMI ≥23 · 12 mg weekly vs placebo · Trial N=537 · Treatment-regimen estimand. Results & methods ↗

Phase 2 obesity dose-finding studyMean body-weight change at week 48Body weight decreased 24.2% · 48 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed results

Mean body-weight change at week 48 · 48 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
24.2%
Placebo / comparator
2.1%

Adults with obesity or overweight and a weight-related condition, without type 2 diabetes · 12 mg once weekly vs placebo · Trial N=338 · Least-squares mean; week-48 secondary endpoint. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Same study · week-24 primary endpointAt 24 weeks, mean body-weight change was −17.5% with 12 mg and −1.6% with placebo.

At week 24, the primary endpoint showed 17.5% mean weight change with 12 mg and 1.6% with placebo.

Diabetes-focused studies

These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.

Phase 2 type 2 diabetes studyMean body-weight change at week 36 (secondary outcome)Body weight decreased 16.9% · 36 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed results

Mean body-weight change at week 36 (secondary outcome) · 36 weeks

Study focus: Weight change in type 2 diabetes

Investigational regimen
16.9%
Placebo / comparator
3%

Adults with type 2 diabetes treated with diet and exercise or stable metformin · 12 mg once weekly vs placebo · Trial N=281 · Least-squares mean; secondary weight outcome. The primary endpoint was HbA1c change at week 24.. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Same study · primary HbA1c endpointAt week 24, HbA1c decreased by 2.02 percentage points with retatrutide 12 mg, 0.01 points with placebo, and 1.41 points with dulaglutide 1.5 mg.

The study was designed primarily to assess glycemic control in type 2 diabetes.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

Phase 3 · peer-reviewed

Obstructive sleep apnea substudies

Week-80 apnea–hypopnea index (AHI) results use the hybrid-treatment estimand; populations are reported separately. Retatrutide remains investigational.

TRIUMPH-1-OSA · without type 2 diabetes

In 243 adults with moderate-to-severe OSA and overweight or obesity without type 2 diabetes, week-80 mean AHI changes were −22.9, −34.3 and −31.7 events/hour with retatrutide 4, 9 and 12 mg, versus −9.9 with placebo. The placebo-adjusted differences were −13.0, −24.4 and −21.9 events/hour, respectively.

TRIUMPH-2-OSA · with type 2 diabetes

In 448 adults with moderate-to-severe OSA and overweight or obesity with type 2 diabetes, week-80 mean AHI changes were −19.2, −24.7 and −25.4 events/hour with retatrutide 4, 9 and 12 mg, versus −10.3 with placebo. Placebo-adjusted differences were −8.9, −14.4 and −15.1 events/hour, respectively.

Read the NEJM publication ↗

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagonTargeted
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3Initiated
Milestone → next

Latest: Knee-osteoarthritis results from TRIUMPH-4 and the TRIUMPH-1 OA cohort were published in November 2026. Separate TRANSCEND-T2D-2 sponsor topline and published weight and OSA results remain shown below.

Next: Further weight-management, diabetes, cardiovascular and kidney outcome results from the TRIUMPH and TRANSCEND programs.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies9 records

Phase 3

TRIUMPH-1

Weight management
Study: CompletedResults: Published weight and OA results; primary ACR pain estimates shownStatus reviewed November 2026

Adults with obesity or overweight without type 2 diabetes; the master protocol includes osteoarthritis and sleep-apnea substudies. OSA substudy outcomes were published in NEJM in October 2026. Knee-pain outcomes are now shown separately using the primary ACR efficacy-estimand estimates; the related NEJM publication appeared November 8, 2026.

Phase 3

TRIUMPH-2

Weight management with type 2 diabetes
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

Adults with obesity or overweight and type 2 diabetes; the master protocol includes an obstructive-sleep-apnea substudy. OSA substudy outcomes were published in NEJM in October 2026.

Phase 3

TRIUMPH-3

Weight management with cardiovascular disease
Study: CompletedResults: Sponsor results shown aboveStatus reviewed November 2026

Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. This is a weight-loss efficacy study, not a dedicated cardiovascular-outcomes trial.

Phase 3

TRIUMPH-4

Weight management with knee osteoarthritis
Study: CompletedResults: Published weight and OA results; primary ACR pain estimates shownStatus reviewed November 2026

Adults with obesity or overweight and knee osteoarthritis; weight and knee-pain outcomes. Knee-pain outcomes are now shown separately using the primary ACR efficacy-estimand estimates; the related NEJM publication appeared November 8, 2026.

Phase 3

TRIUMPH-5

Comparative weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Head-to-head comparison with tirzepatide in adults with obesity.

Phase 3

TRIUMPH-6

Weight maintenance
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Maintenance of weight reduction after a retatrutide lead-in period in adults with obesity.

Phase 3

TRIUMPH-7

Weight management with chronic low-back pain
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight and chronic low-back pain; studies weight and pain outcomes.

Phase 3b

TRIUMPH-8

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults without type 2 diabetes who have obesity or overweight; placebo-controlled weight-management study.

Phase 3

TRIUMPH-9

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults without type 2 diabetes who have obesity or overweight; evaluates dose-escalation approaches.

Phase 2 studies1 record

Related conditions and outcomes

Phase 3 studies5 records

Phase 3

SYNERGY-Outcomes

Liver outcomes (MASLD)
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Shared master protocol testing retatrutide and tirzepatide in adults with high-risk MASLD; evaluates major adverse liver outcomes. The two medicines are separate study arms.

Phase 3

TRANSCEND-T2D-1

Glycemic control in type 2 diabetes
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

Adults with type 2 diabetes inadequately controlled by diet and exercise; positive sponsor topline reported in March 2026.

Phase 3

TRANSCEND-T2D-2

Glycemic control in type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor; retatrutide compared with semaglutide 2 mg. Lilly reported 80-week topline results; full peer-reviewed data are pending.

Phase 3

TRANSCEND-T2D-3

Glycemic control with kidney impairment
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with type 2 diabetes and moderate or severe renal impairment with inadequate control on basal insulin, with or without other background therapy.

Phase 3

TRIUMPH-Outcomes

Cardiovascular and kidney outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Event-driven cardiovascular and kidney outcomes in adults with obesity plus established atherosclerotic cardiovascular disease and/or chronic kidney disease.

Phase 2 studies1 record